Systematic screening of GE Healthcare Technologies Inc. (GEHC) reveals a medical technology enterprise trading at a notable discount to its 52-week high of $89.77, with the current price of $61.51 representing a 31% compression. The company's valuation multiples present an intriguing research perspective: a trailing P/E of 14.47 positions GEHC at a material discount relative to typical medtech peers, while the P/S ratio of 1.32 reflects moderate pricing for a healthcare equipment manufacturer with established market presence.

The profitability profile demonstrates institutional-grade metrics across several dimensions:

• ROE of 18.75% indicates strong equity efficiency despite a leveraged capital structure
• Operating margin of 12.63% reflects disciplined cost management in a competitive medical device landscape
• Net margin of 9.1% suggests profitable operations even amid sector pricing pressures
• Gross margin of 39.14% provides adequate cushion for R&D investment and commercial infrastructure

The fundamental model flags two contrasting signals: revenue growth of 5.97% year-over-year demonstrates steady top-line expansion, yet EPS declined 12.27% over the same period, indicating margin compression or elevated operational costs. The debt-to-equity ratio of 0.97 remains manageable but warrants monitoring given the capital-intensive nature of medical technology development. A beta of 0.87 suggests lower volatility than the broader market, consistent with healthcare's defensive characteristics.

Relative to peers including Boston Scientific (BSX), Edwards Lifesciences (EW), and IDEXX Laboratories (IDXX), GEHC's current ratio of 1.37 and P/B of 3.6 position the company as a value-oriented medtech play with solid liquidity metrics. The screener highlights this profile for portfolios emphasizing healthcare exposure at below-sector-average valuation multiples.